APTARGROUP, Inc. (ATR) is a leading global supplier of a broad range of innovative dispensing, sealing, and active packaging solutions used by a variety of end markets, such as personal care, home care, beauty, food & beverage, prescription drug, and consumer health care sectors. Incorporated in 1989 and headquartered in Crystal Lake, Illinois, this pioneering organization has a global footprint in over 20 countries, employing about 13,000 people worldwide.
APTARGROUP, Inc. operates through three business segments - Beauty + Home, Pharma, and Food + Beverage. It expertly produces and provides innovative packaging and dispensing systems that enhance the convenience, functionality, and safety of its clients' products. The company's range of offerings includes spray pumps, lotion pumps, aerosol valves, closures, caps, roll-ons, droppers, and dispensing systems that can meet various customers' needs.
APTARGROUP is renowned for maintaining stringent quality systems, ensuring that their products meet the high standards required by their customers, and comply with all local and global legislative regulations. With a strong focus on sustainability, APTARGROUP, Inc. is committed to reducing its environmental footprint, enhancing its social impact, and driving governance. This commitment reflects in their efforts to use their innovation process to develop solutions that not only meet customers' needs, but also contribute to a more sustainable world.
APTARGROUP has a consistent history of delivering strong financial performance. Its resilient and diversified business model, a robust portfolio of innovative products, strong relationships with leading brands worldwide, and its continued focus on innovation and sustainability have helped the company to not only navigate through market fluctuations but also thrive.
In conclusion, APTARGROUP, Inc. isn't just a packaging company; it's a global leader set on improving daily life for everyone, everywhere. Whether it's developing a new delivery system for life-saving medication, creating packaging solutions that keep food fresh for longer, or working towards a greener world, APTARGROUP does it with skill, conviction, and a dedication to making the world a better place. The company's inherent ability to combine innovative design, functional performance, regulatory expertise, and cost-effectiveness makes it a partner of choice for many consumer product companies. APTARGROUP, Inc. continues to excel in its field, marking a significant presence in the packaging industry worldwide.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
AptarGroup, Inc. (ATR), a key player in medical instruments and supplies, shows a potential upside of 36.73% with its stock trading below key moving averages. The company has a market capitalization of $7.91 billion, a forward P/E ratio of 19.70, and a dividend yield of 1.54%. Analyst sentiment is largely positive, with an average target price of $170.14, indicating strong confidence in its future growth and strategic direction.
Aptar Pharma has partnered with Massachusetts General Hospital to create a translational research platform aimed at developing a predictive, data-driven model for nose-to-brain (N2B) drug delivery. This collaboration seeks to improve candidate selection, optimize formulation, and accelerate the development of therapies for neurological and central nervous system disorders. The goal is to transform N2B delivery into a more predictable pathway, providing long-term value across various CNS applications.
AptarGroup's Chief Human Resources Officer, Shiela Vinczeller, sold 765 shares of the company's common stock on September 2, 2026, at a weighted average price of $130.3693 per share. This transaction was reported in a Form 4 filing with the SEC on September 3, 2026. Following the sale, Vinczeller directly owns 26,313 shares of AptarGroup common stock.
AptarGroup, Inc. announced the appointment of Gael Touya as its new President and Chief Executive Officer, effective September 1, 2026. Touya also joins the company's Board of Directors, which has expanded from ten to eleven members. He succeeds Stephan B. Tanda, who retired from the CEO position.
Aptar Active Material Science has launched its Activ-Film™ technology for the first time with a commercialized capsule-based Dry Powder Inhalation (DPI) drug product. This technology, which leverages the 3-Phase Activ-Polymer™ platform, is integrated into the blister packaging to protect the dry powder capsules without direct contact. This marks a significant milestone for Aptar in advancing drug delivery performance and patient experience for complex and sensitive drugs.